Cordant Health Solutions® offers a managed medication-assisted treatment (MAT) pharmacy program that focuses on supporting clinicians who treat patients for opioid use disorder using buprenorphine or other addiction treatment medications. The program works by delivering addiction treatment medication dispensed by Cordant’s pharmacy to the patient during the time of their treatment visit, or for telemedicine programs, to the patient’s home.
Watch this video to learn more about the findings revealed in the study. Presented by Elizabeth Kolb, Cordant’s senior director of corporate development and strategy and co-author of the study.
A peer-reviewed study published in the Journal of Substance Abuse Treatment demonstrated that patients using Cordant’s managed medication-assisted treatment (MAT) pharmacy program:
Cordant’s on-site managed MAT pharmacy program eliminates many of the barriers to treatment that patients face including poor treatment at retail pharmacies, challenges with transportation and limited or no availability of medication when needed, and can help improve patient adherence to their treatment plan.
In a recent survey, 93% of patients said that they are more likely to adhere to their treatment plans and attend their appointments when they receive medication at their doctor’s office through Cordant’s program, and 98% said they feel that Cordant’s pharmacy coordinators treat them with respect and care about their well-being.
NPS is a measure of customer satisfaction and loyalty, with scores over 50 considered “best in class.” Cordant’s score was higher than many popular brands such as Southwest (71), Costco (76), and USAA (72).
Patients in Cordant’s buprenorphine program showed significantly higher retention rates, especially in the early part of treatment
Patients in Cordant’s program had fewer drug-related ER visits
Patients in Cordant’s program experienced fewer relapse events
Source: Analysis of 154 patients 90 days or less in treatment prior to Cordant’s clinic-based managed pharmacy program; Nov. 2016–Oct. 2017 and 154 patients 90 days or less in treatment participating in program; Nov. 2017–Oct. 2018
Please complete this form to request more information about our managed pharmacy solution.